Javascript must be enabled to continue!
Diabetic Endothelial Cell Glycogen Synthase Kinase 3β Activation Induces VCAM1 Ectodomain Shedding
View through CrossRef
Soluble cell adhesion molecules (sCAMs) are secreted ectodomain fragments of surface adhesion molecules, ICAM1 and VCAM1. sCAMs have diverse immune functions beyond their primary function, impacting immune cell recruitment and activation. Elevated sVCAM1 levels have been associated with poor cardiovascular disease (CVD) outcomes, supporting its role as a potential diagnostic marker and therapeutic target. Inhibiting sVCAM1 release or interaction with immune cells could offer cardioprotection in conditions such as diabetes. Membrane bound surface adhesion molecules are widely expressed in a wide variety of cell types with higher expression in endothelial cells (ECs), but the source of sCAMs in the circulation is not clear. Hypothesizing that endothelial cells (ECs) could be a potential source of sCAMs, this study investigated whether dysfunctional EC signaling mechanisms during diabetes cause VCAM1 ectodomain shedding. Our results from samples from a inducible diabetic mouse model revealed increased sVCAM1 plasma levels in diabetes. Protein analysis indicated upregulated VCAM1 expression and metalloproteases ADAM10 and ADAM17 in diabetic ECs. ADAMs are known for proteolytic cleavage of adhesion molecules, contributing to inflammation. GSK3β, implicated in EC VCAM1 expression, was found to be activated in diabetic ECs. GSK3β overexpression in control ECs increased ADAM10/17 and VCAM1. A GSK3β inhibitor reduced active GSK3β and VCAM1 ectodomain shedding. These findings suggest that diabetic ECs with elevated GSK3β activity led to VCAM1 upregulation and ADAM10/17-mediated sVCAM1 shedding. This mechanism underscores the potential therapeutic role of GSK3β inhibition in reducing the levels of circulating sVCAM1. The complex roles of sCAMs extend well beyond CVD. Thus, unraveling the intricate involvement of sCAMs in the initiation and progression of vascular disease particularly in diabetes, holds significant therapeutic potential.
Title: Diabetic Endothelial Cell Glycogen Synthase Kinase 3β Activation Induces VCAM1 Ectodomain Shedding
Description:
Soluble cell adhesion molecules (sCAMs) are secreted ectodomain fragments of surface adhesion molecules, ICAM1 and VCAM1.
sCAMs have diverse immune functions beyond their primary function, impacting immune cell recruitment and activation.
Elevated sVCAM1 levels have been associated with poor cardiovascular disease (CVD) outcomes, supporting its role as a potential diagnostic marker and therapeutic target.
Inhibiting sVCAM1 release or interaction with immune cells could offer cardioprotection in conditions such as diabetes.
Membrane bound surface adhesion molecules are widely expressed in a wide variety of cell types with higher expression in endothelial cells (ECs), but the source of sCAMs in the circulation is not clear.
Hypothesizing that endothelial cells (ECs) could be a potential source of sCAMs, this study investigated whether dysfunctional EC signaling mechanisms during diabetes cause VCAM1 ectodomain shedding.
Our results from samples from a inducible diabetic mouse model revealed increased sVCAM1 plasma levels in diabetes.
Protein analysis indicated upregulated VCAM1 expression and metalloproteases ADAM10 and ADAM17 in diabetic ECs.
ADAMs are known for proteolytic cleavage of adhesion molecules, contributing to inflammation.
GSK3β, implicated in EC VCAM1 expression, was found to be activated in diabetic ECs.
GSK3β overexpression in control ECs increased ADAM10/17 and VCAM1.
A GSK3β inhibitor reduced active GSK3β and VCAM1 ectodomain shedding.
These findings suggest that diabetic ECs with elevated GSK3β activity led to VCAM1 upregulation and ADAM10/17-mediated sVCAM1 shedding.
This mechanism underscores the potential therapeutic role of GSK3β inhibition in reducing the levels of circulating sVCAM1.
The complex roles of sCAMs extend well beyond CVD.
Thus, unraveling the intricate involvement of sCAMs in the initiation and progression of vascular disease particularly in diabetes, holds significant therapeutic potential.
Related Results
Abstract 2819: Mass spectrometry imaging reveals heterogeneous glycogen metabolism in non small cell lung cancer
Abstract 2819: Mass spectrometry imaging reveals heterogeneous glycogen metabolism in non small cell lung cancer
Abstract
Lung cancer is the leading cause of cancer related death worldwide, with a high mortality rate even when diagnosed at an early stage. Identifying the unique...
Glycogen metabolism in cultured chick hepatocytes: A morphological study
Glycogen metabolism in cultured chick hepatocytes: A morphological study
AbstractUltrastructural and autoradiographic observations of cultured chick hepatocytes under the following conditins are described: Induction of glycogen synthesis with glucose al...
Physiological Responses to Hypoxia in the Absence of Brain Glycogen
Physiological Responses to Hypoxia in the Absence of Brain Glycogen
Background and Hypothesis: Glycogen is a highly branched polymer of glucose and is an important form of energy storage in mammals. The brain is able to form glycogen in astrocytes ...
Investigation of Potential Glycogen Synthase Kinase 3 Inhibitors Using Pharmacophore Mapping and Virtual Screening
Investigation of Potential Glycogen Synthase Kinase 3 Inhibitors Using Pharmacophore Mapping and Virtual Screening
Glycogen synthase kinase‐3 is a serine/threonine kinase that has attracted significant drug discovery attention in recent years. To investigate the identification of new potential ...
SERGE, the subcellular site of initial hepatic glycogen deposition in the rat: a radioautographic and cytochemical study.
SERGE, the subcellular site of initial hepatic glycogen deposition in the rat: a radioautographic and cytochemical study.
Hormonal control of hepatic glycogen and blood glucose levels is one of the major homeostatic mechanisms in mammals: glycogen is synthesized when portal glucose concentration is su...
Glycogen‐Synthase Phosphatase Activity in Rat Liver
Glycogen‐Synthase Phosphatase Activity in Rat Liver
Three subfractions of glycogen synthase b (termed b1, b2, b3) have been isolated from the glycogen fraction of dog liver on the basis of a different affinity for DEAE‐cellulose. Th...
Glycogen and its metabolism: some new developments and old themes
Glycogen and its metabolism: some new developments and old themes
Glycogen is a branched polymer of glucose that acts as a store of energy in times of nutritional sufficiency for utilization in times of need. Its metabolism has been the subject o...
The role of glycogen synthase phosphatase in the glucocorticoid-induced deposition of glycogen in foetal rat liver
The role of glycogen synthase phosphatase in the glucocorticoid-induced deposition of glycogen in foetal rat liver
1. The mechanism that underlies the induction of glycogen synthesis in the foetal rat liver by glucocorticoids was reinvestigated in conditions where the accumulation of glycogen i...

